ClinicalTrials.gg
Active, not recruitingNCT07360275VICTOR-HTNUpdated Sep 21, 2026

A Study of VCT220 in Participants With Hypertension and Obesity or Overweight

A Phase 2 interventional study of VCT220 Tablet and VCT220 Placebo Tablet in Hypertension, sponsored by Vincentage Pharma Co., Ltd. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Vincentage Pharma Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 408 studies in Hypertension with a site in China — 123 open to participants now, 146 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
193rd of 306
160 · median 255
Started
2026
with 36 others
Phase 2
14 of 408
5 open now
Primary completion
2026-10
later than 57 of 145 live
Registered
366th of 408
by date

Among the 408 studies in Hypertension with a site in China, this one is the 193rd largest by planned enrollment of the 306 interventional ones that give a count, is one of 37 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 57 of the 145 other live ones, and was the 366th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

123 of the 408 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 408 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18 to 75 years (inclusive) at the time of screening.
  2. (BMI) ≥ 24 kg/m² at screening.
  3. Diagnosed with primary hypertension, with office seated systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg at both screening and baseline.
  4. Either treatment-naïve to antihypertensive therapy for ≥ 30 days prior to screening, or receiving a stable dose for ≥ 30 days of one or two of the following classes of antihypertensive medications: renin-angiotensin system inhibitors (ARB/ACEI), calcium channel blockers (CCB), or diuretics.
  5. Has at least one self-reported history of unsuccessful weight loss through dietary control.
  6. Willing and able to maintain a stable residence and remain contactable throughout the study, and to adhere to regular lifestyle routines as well as dietary and exercise management during the trial.
  7. Has a full understanding of the study procedures, is able to communicate effectively with the investigator, understands and is willing to comply with all study requirements, and voluntarily provides written .

Exclusion criteria

Exclusion Criteria

  1. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).
  2. History of or current secondary hypertension.
  3. Office seated systolic blood pressure (SBP) ≥ 170 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg at screening or baseline, or presence of a hypertensive emergency.
  4. A decrease in office seated SBP of ≥ 20 mmHg or a decrease in office seated DBP of ≥ 10 mmHg at baseline compared with screening.
  5. Presence of orthostatic hypotension at screening, defined as a decrease in office SBP of ≥ 15 mmHg or DBP of ≥ 7 mmHg upon transition from the seated to standing position.
  6. A difference of ≥ 20 mmHg in office seated SBP between the left and right upper arms at screening or baseline.
  7. Treatment with any marketed or drug with a glucagon-like peptide-1 (GLP-1) receptor agonist mechanism within 1 year prior to screening.
  8. Self-reported or documented body weight change of ≥ 5 kg within 3 months prior to screening.
  9. History of or current type 1 or type 2 diabetes mellitus.
  10. History of or current within the past 5 years, except for adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.
  11. History of or current major cardiovascular or cerebrovascular disease.
  12. History of or current severe gastrointestinal disease or prior major gastrointestinal surgery.
  13. active or unstable severe major depressive disorder or other severe psychiatric disorders within 2 years prior to screening; or any history of suicide attempt.
  14. Patient Health Questionnaire-9 (PHQ-9) score ≥ 15 at screening, or a positive response to Item 9.
  15. Pregnant or breastfeeding women; or men or women of who are unwilling to use highly effective throughout the study and for 3 months after the last dose, or who plan to conceive, donate sperm, or donate oocytes during this period; or women with a positive pregnancy test at screening.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    VCT220 80mg

    Participants will receive VCT220 orally everyday. Starting from 20mg and maintaining at 80mg

    Drug: VCT220 Tablet

  • Placebo comparator
    Placebo

    Participants will receive placebo orally.

    Drug: VCT220 Placebo Tablet

  • Experimental
    VCT220 160mg (1)

    Participants will receive VCT220 orally everyday. Starting from 20mg and maintaining at 160mg

    Drug: VCT220 Tablet

  • Experimental
    VCT220 160mg (2)

    Participants will receive VCT220 orally everyday. Starting from 40mg and maintaining at 160mg

    Drug: VCT220 Tablet

Interventions

  • Administered orally, with or without food.

  • DrugVCT220 Placebo Tablet

    Administered orally, with or without food.

06

What researchers measure

Primary outcomes

  1. Change from baseline in office seated systolic blood pressure (SBP) at Week 20

    Measured In mmHg

    Time frame: From baseline to week 20

Secondary outcomes

  1. Change from baseline in office seated diastolic blood pressure (DBP) at Week 20

    Measured in mmHg

    Time frame: From baseline to week 20

  2. Change from baseline in 24-hour ambulatory blood pressure monitoring (ABPM) systolic blood pressure and diastolic blood pressure at Week 20

    Measured in mmHg

    Time frame: From baseline to week 20

  3. Proportion of participants achieving the standard blood pressure target (< 140/90 mmHg) based on office seated blood pressure at Week 20

    Measured in percentage

    Time frame: From baseline to week 20

  4. Proportion of participants achieving the intensive blood pressure target (< 130/80 mmHg) based on office seated blood pressure at Week 20

    Measured in percentage

    Time frame: From baseline to week 20

  5. Changes in body weight at week 20

    Measured in Kg

    Time frame: From baseline to week 20

  6. Adverse events, including treatment-emergent adverse events (TEAEs), serious adverse events (SAEs)

    Count of events

    Time frame: From baseline to week 20

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2026, 7 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 7 months is below that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 22, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Dec 20, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07360275
Lead sponsor
Vincentage Pharma Co., Ltd
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Mar 1, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Sep 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VCT220

Start the discussion